CRISPR: Hearing all about it

The Boards of Appeal of the European Patent Office (EPO) have set aside four-and-a-half days in January 2020 for the hearing in T0844/18, the first appeal relating to CRISPR Cas9 technology in eukaryotes. The central discussion in this hearing will be about the formal requirements for claiming priority as this is an appeal by the Broad Institute, MIT and Harvard (Broad et al) to the revocation of their lead patent EP2771468.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

Biotechnology

Closing the women's health gap offers ‘benefits for all’

7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.

Biotechnology

Novartis bets $2bn on biologics as Xolair patents fade

27 March 2026 The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.